Cardiac involvement in patients with Fabry disease: from pathophysiology to imaging and treatment

Dear Colleagues,

This special issue of Reviews in Cardiovascular Medicine will focus on “Cardiac involvement in patients with Fabry disease”. Fabry disease is a rare, X-linked, inherited lysosomal storage disorder caused by pathogenic variants in the GLA gene, leading to deficiency of the α-galactosidase A enzyme activity. The enzymatic deficit causes accumulation of lysosomal glycosphingolipids in cells of affected tissues, including all the cardiac cellular types. Fabry cardiomyopathy manifests as left ventricular hypertrophy mimicking hypertrophic cardiomyopathy.

Following the introduction of disease-specific enzyme replacement therapy, early diagnosis and treatment have become crucial to slow disease progression and prevent major organ damage. Advances in cardiac imaging together with the development of new therapies, including chaperone molecules, modified enzymes, substrate reduction therapy, and genetic treatments, are rapidly improving the diagnostic and therapeutic approach to cardiac Fabry disease.

The aim of this Special Issue is to provide the readers with a comprehensive overview on state-of-the-art knowledge about pathophysiology, cardiac imaging and biomarkers, treatment, and prognosis of Fabry cardiomyopathy.

We are therefore looking forward to receiving your review articles or full research papers on this topic.

A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page.

Dr. Maurizio Pieroni

Guest Editor

Guest Editor(s):

Dr. Maurizio Pieroni
mauriziopieroni@yahoo.com
San Donato Hospital, Italy
Message from the Editor-in-Chief

Reviews in Cardiovascular Medicine was launched in 2000 by MedReviews, LLC, in New York, NY. This journal was conceived to fill a critical gap for clinicians who were struggling with a rapidly expanding knowledge base in cardiovascular medicine with the convergence of basic science, clinical epidemiology, and therapeutic clinical trials. The founding co-editors were David P. Faxon, MD, past president of the American Heart Association, and Norman E. Lepor, MD, who is considered a luminary in interventional cardiology. The contributing editorial board grew over time and Dr. Peter A. McCullough, MD, MPH ascended from contributing, to associate, to co-editor of the Journal. In 2018, the Journal took its next big step under the leadership of Dr. McCullough as editor-in-chief to become a truly international publication. Its offices moved to IMR Press in Hong Kong, and the editorial board was made more inclusive and representative of the world-wide contributors in academic cardiology. Additionally, the journal brought on expertise in translational medicine to help face the future of molecular medicine and its role in cardiovascular disease. Today Reviews in Cardiovascular Medicine is considered a top tier journal in cardiology with timely and comprehensive reviews covering all aspects of cardiovascular medicine including atherosclerosis, myocardial disease, arrhythmias, and valvular heart disease. The scope of papers ranges from population science, applied basic investigation, in-vitro diagnostics, and evidence-based strategy and therapeutic trials involving both pharmacologic intervention and interventional devices. The highly integrative style of the Journal anchored with evidence tables and instructive figures has garnered many citations over the years and many guidelines documents have relied upon works published in Reviews in Cardiovascular Medicine. Supplement and focus issues have been very popular among the readership and often are viewed as the most up-to-date compilations of new acknowledge in cardiology and related specialties. The future is bright for academic cardiovascular medicine and Reviews in Cardiovascular Medicine is well positioned along side the clinician-investigator in the years to come as a trusted source of critical information and analysis.

Editor-in-chief:

Dr. Peter A. McCullough
peteramccullough@gmail.com
Baylor University Medical Center, Baylor Heart and Vascular Institute, Baylor Jack and Jane Hamilton Heart and Vascular Hospital, Dallas, TX, United States

Submission Deadline: 31 January 2022
Submission: https://jour.ipublishment.com/imr/access/login
Contact us: RCMeditorial@imrpress.org